Expert Interview
Exploring the potential impact of the FDA's approval of inavolisib, palbociclib, and fulvestrant for treating endocrine-resistant, PIK3CA-mutated, HR-positive advanced breast cancer on future oncology patient care.
Ticker(s): RHHBYInstitution: University of Cambridge
- Clinical Senior Research Associate and Academic Consultant in Breast Cancer Therapeutics at the University of Cambridge.
- Currently manages 30 patients with HR+/HER- breast cancer each month.
- Focus on Early phase breast cancer clinical trials with expertise in first-in-human studies & drug combination trials, new small molecule & antibody therapeutics and the development of pharmacodynamic and predictive biomarkers.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
